Ammar Sabilarrohman
As of June 1, 2026, Japan will officially classify cannabinol (CBN) as a designated drug (shitei yakubutsu), effectively criminalizing its manufacture, import, sale, and possession. This decisive move marks a significant shift in the nation’s stringent drug policy, closing a legal loophole that had allowed the hemp-derived compound to proliferate in retail stores, from trendy wellness boutiques to ubiquitous discount chains like Don Quijote.
For many residents and tourists, the sudden illegality of a substance widely marketed for sleep and relaxation comes as a shock. However, for the Japanese Ministry of Health, Labour and Welfare (MHLW), the ban represents a necessary intervention to curb the rise of potent, psychoactive products that have increasingly blurred the line between health supplements and prohibited narcotics.
The Core Facts: What Changes on June 1?
Starting June 1, 2026, CBN will join the ranks of controlled substances under Japan’s Pharmaceutical and Medical Device Act. This means that even trace amounts of the compound in gummies, oils, or vape cartridges will be treated with the same legal severity as other prohibited substances.
The consequences of possession are severe. Under Japan’s Cannabis Control Act and associated drug regulations, the state maintains a zero-tolerance policy. Individuals found in possession of designated drugs face potential criminal prosecution, including heavy fines and significant prison sentences. Notably, there is no "grandfather clause" for products purchased prior to the ban; all existing inventory must be disposed of, and any remaining supply held by individuals will be considered contraband.
A Chronology of the Cannabinoid Market in Japan
To understand the current crackdown, one must look at the evolution of Japan’s relationship with hemp derivatives.
- The CBD Era (Pre-2020): Japan permitted cannabidiol (CBD) provided it was derived from mature hemp stalks and seeds, and crucially, contained zero detectable traces of tetrahydrocannabinol (THC). This created a robust, albeit strictly regulated, market for wellness products.
- The Rise of the Gray Market (2021–2024): As regulators began tightening laws against synthetic cannabinoids (often marketed as "legal highs"), manufacturers sought alternatives. CBN, a natural byproduct of aging THC, filled this vacuum. Because it was not explicitly listed as a prohibited substance, retailers operated under the assumption that it was legal.
- The Turning Point (May 2025): The market’s "wild west" nature reached a breaking point in May 2025, when a university student in Yamanashi Prefecture suffered a serious injury after falling from a dormitory window. The incident was linked to the consumption of high-potency CBN-infused cookies, sparking a national outcry and a government-led investigation into the safety of unregulated cannabinoids.
- The Regulatory Hammer (March 2026): Following a public consultation and an MHLW review, the government officially announced the addition of CBN to the list of designated drugs, effectively giving the industry less than three months to liquidate or destroy its stock.
Supporting Data: Potency and Public Safety
The transition from "wellness aid" to "public health concern" was largely driven by the evolution of product manufacturing. While initial CBN products were marketed at modest doses (25–100mg), the competitive nature of the gray market led companies to push the envelope.
Government investigators found products on the shelves containing up to 1,000mg of CBN per serving. At these concentrations, the substance ceased to act as a mild sedative and began producing distinct psychoactive effects. Data presented to the MHLW indicated that the lack of standardized testing and labeling meant consumers were often unaware of the potency of the products they were consuming.
Furthermore, the lack of quality control led to instances of cross-contamination. Investigations, such as the one involving the resignation of Suntory CEO Takeshi Niinami in 2025—after his personal supplement order was found to contain illegal THC—highlighted the volatility of the entire sector. In the eyes of Japanese authorities, if a product is not strictly vetted, it is presumed to be a public health risk.
Official Responses and Industry Discontent
The government’s position remains firm: the health of the public outweighs the economic interests of the burgeoning cannabinoid industry. The MHLW has maintained that the psychotropic potential of high-dose CBN, combined with the lack of long-term clinical safety data, necessitates a total ban.
Conversely, industry stakeholders are expressing frustration. The CBN market was estimated to be worth approximately ¥10 billion annually. Shop owners argue that they were operating in good faith within the established legal framework. A Shibuya-based retailer noted in a recent interview, "We have been providing a safe alternative for people struggling with chronic insomnia. To shut down the entire industry overnight without offering a pathway to regulation is a massive blow to both retailers and the consumers who rely on these products."
Industry groups attempted to lobby for strict age restrictions and potency caps, but the Yamanashi incident hardened the government’s resolve, leaving little room for compromise.
Implications for Residents and Travelers
The implications of this ban are far-reaching, particularly for those who have integrated these products into their daily routines.
For Foreign Residents
The most immediate change is the need to purge household inventory. Residents are advised to dispose of any CBN-containing products before June 1. Furthermore, there is a lesson in the Niinami case: in Japan, ignorance of an ingredient’s content is not a legal defense. Residents should be wary of any "wellness" supplement ordered from overseas, as international standards for purity often do not align with Japan’s strict "zero-THC" and "no-designated-drug" requirements.
For Tourists
Travelers should exercise extreme caution. Bringing any cannabis-derived product—even those that are legal in the traveler’s home country—into Japan is a high-risk activity. Airport customs have become increasingly vigilant, and possession of prohibited substances at the border can lead to immediate detention, deportation, and a permanent ban from re-entering the country. Travelers are advised to check their bags and vanity cases thoroughly to ensure no gummies, oils, or vapes containing CBN or THC are accidentally left inside.
The Medical Exception: A Narrow Doorway
The MHLW has outlined a path for a "medical exception," but it is far from a simple prescription. To qualify, a patient must prove they have a serious, treatment-resistant condition that cannot be managed by conventional pharmaceuticals. This requires:
- A diagnosis and endorsement from a qualified Japanese physician.
- A comprehensive review by an academic society.
- Formal approval from the Narcotic Control Division in Tokyo.
This process is conducted entirely in Japanese and is designed to be restrictive. It is not intended for individuals seeking relief for common stress or sleep disorders. Consequently, for the average person, there is effectively no legal access to CBN as of June 1.
The Future: What About CBD?
It is vital to distinguish that CBD is not being banned. The Japanese government continues to allow the sale of CBD, provided it is 100% THC-free. However, the market is undergoing a period of intense scrutiny.
Consumers who rely on CBD for wellness should prioritize transparency. Reputable vendors in Japan now provide a Certificate of Analysis (COA) for every batch, confirming that third-party testing has verified the absence of THC and other restricted cannabinoids. If a product does not have a COA, consumers should treat it with suspicion.
As the industry moves forward, observers speculate that the market will shift toward other cannabinoids like CBG (cannabigerol) or CBC (cannabichromene), which remain currently unregulated. However, the fate of CBN serves as a cautionary tale: in Japan, the "gray area" is not a permanent state, but rather a temporary period of grace before the government chooses to regulate, restrict, or entirely eliminate a substance from the market.
For now, the era of accessible CBN in Japan is coming to a close, and the nation is returning to a more conservative, strictly controlled approach to the cannabis plant and its derivatives.
Asep Darmawan
Nana Wu
